• Home
  • Search Results
  • Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method.

Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method.

Clinical pharmacology and therapeutics (2006-08-08)
Themba T Ndovi, Leena Choi, Brian Caffo, Teresa Parsons, Sharon Baker, Ming Zhao, Charles Rohde, Craig W Hendrix

The male genital tract is a complex collection of anatomically and biochemically distinct compartments that contribute to the ejaculate. Understanding the pharmacokinetics in these compartments should inform rational therapeutics involving these glands. Nineteen men were administered a single dose of 600 mg chloroquine (base) and 975 mg aspirin before providing a semen sample by masturbation with fractionation into a 5-compartment collection device. Fractions were assayed for fructose (unique seminal vesicle marker), prostate-specific antigen (unique prostate marker), salicylate, and chloroquine. Seminal vesicle and prostate concentrations of salicylate and chloroquine were estimated via a novel analytic method involving a multilevel latent-variable model implemented by use of Bayesian methods. The geometric mean chloroquine semen/blood ratio was 4.02 (95% confidence interval [CI], 2.36-6.86); for salicylate, the primary metabolite of aspirin, the semen/blood ratio was 0.10 (95% CI, 0.08-0.14). The estimated mean prostate/seminal vesicle ratio for salicylate, 0.38 (95% CI by Bayesian methods, 0.12-0.73), was consistent with our hypothesis that salicylate would achieve higher concentrations in the seminal vesicle than in the prostate. Chloroquine, however, did not demonstrate a statistically significant seminal vesicle/prostate difference (4.41; 95% CI by Bayesian methods, 0.14-30.52). We successfully demonstrated the quantitative, noninvasive estimation of drug concentrations in the prostate gland fluid distinct from the seminal vesicle fluid using our optimized method of split-ejaculate collection and a novel mixed-effects model with Bayesian estimation. Our methods can be applied to gland-specific quantitation of drugs and other substances of interest, thus enabling pharmacokinetic, pharmacodynamic, and pathophysiologic studies to inform rational therapeutics within different glands of the male genital tract.

Product Number
Product Description

Salicylic acid, BioXtra, ≥99.0%
Salicylic acid, suitable for plant cell culture
Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance)
Salicylic acid, ACS reagent, ≥99.0%
Salicylic acid, ReagentPlus®, ≥99%
Salicylic acid, ≥99%, FG
Salicylic acid, puriss. p.a., ≥99.0% (T)
Salicylic acid, certified reference material, TraceCERT®
Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Salicylic acid, European Pharmacopoeia (EP) Reference Standard
Salicylic acid, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®